2008 Clinical Practice Guidelines - Canadian Diabetes Association

of Erectile Function. Urology. 1999;54:346-351.
29. Ramanathan R, Mulhall J, Rao S, et al. Prospective correlation
between the International Index of Erectile Function (IIEF)
and Sexual Health Inventory for Men (SHIM): implications for
calculating a derived SHIM for clinical use. J Sex Med. 2007;
4:1334-1344.
30. Valiquette L, Montorsi F, Auerbach S;Vardenafil Study Group.
First-dose success with vardenafil in men with erectile dysfunction
and associated comorbidities: RELY-I. Int J Clin Pract.
2006;60:1378-1385.
31. The Diabetes Control and Complications Trial Research
Group. The effect of intensive diabetes therapy on the development
and progression of neuropathy. Ann Intern Med. 1995;
122:561-568.
32. The Diabetes Control and Complications Trial Research
Group. The effect of intensive treatment of diabetes on the
development and progression of long-term complications in
insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:
977-986.
33. UK Prospective Diabetes Study (UKPDS) Group. Intensive
blood-glucose control with sulphonylureas or insulin compared
with conventional treatment and risk of complications in
patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:
837-853.
34. Azad N, Emanuele NV,Abraira C, et al.The effects of intensive
glycemic control on neuropathy in the VA Cooperative Study
on Type II Diabetes Mellitus (VA CSDM). J Diabetes
Complications. 1990;13:307-313.
35. El-Sakka AI, Hassoba HM, Sayed HM, et al. Pattern of
endocrinal changes in patients with sexual dysfunction. J Sex
Med. 2005;2:551-558.
36. Fonseca V, Seftel A, Denne J, et al. Impact of diabetes mellitus
on the severity of erectile dysfunction and response to treatment:
analysis of data from tadalafil clinical trials. Diabetologia.
2004;47:1914-1923.
37. Rendell MS, Rajfer J,Wicker PA, et al. Sildenafil for treatment
of erectile dysfunction in men with diabetes: a randomized
controlled trial. JAMA. 1999;281:421-426.
38. Boulton AJM, Selam J-L, Sweeney M, et al. Sildenafil citrate
for the treatment of erectile dysfunction in men with type II
diabetes mellitus. Diabetologia. 2001;44:1296-1301.
39. Goldstein I,Young JM, Fischer J, et al.Vardenafil, a new phosphodiesterase
type 5 inhibitor, in the treatment of erectile dysfunction
in men with diabetes: a multicenter double-blind
placebo-controlled fixed-dose study. Diabetes Care. 2003;26:
777-783.
40. Sáenz de Tejada I,Anglin G, Knight JR, et al. Effects of tadalafil
on erectile dysfunction in men with diabetes. Diabetes Care.
2002;25:2159-2164.
41. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for
erectile dysfunction. BJU Int. 2005;96:257-280.
42. Briganti A, Salonia A, Gallina A, et al. Drug insight: oral phosphodiesterase
type 5 inhibitors for erectile dysfunction. Nat
Clin Pract Urol. 2005;2:239-247.
43. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual
dysfunction in patients with cardiovascular disease: recommendations
of the Princeton Consensus Panel. Am J Cardiol.
2000;86:175-181.
44. Herschorn S. Cardiovascular safety of PDE5 inhibitors. Can J
Urol. 2003;10(suppl 1):23-28.
45. Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient
satisfaction outcomes of the AMS 700CX inflatable penile
prosthesis: results of a long-term multicenter study. J Urol.
2000;164:376-380.
S149
COMPLICATIONS AND COMORBIDITIES